- Home
- CRIS
CRIS
Curis Inc.
as 11-13-2025 3:01pm EST
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 18.6M | IPO Year: | 2000 |
| Target Price: | $16.50 | AVG Volume (30 days): | 75.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $4.70 | Next Earning Date: | 11-06-2025 |
| Revenue: | $11,650,000 | Revenue Growth: | 13.56% |
| Revenue Growth (this year): | 2.72% | Revenue Growth (next year): | 8.27% |
Latest Curis Inc. News
CRIS Breaking Stock News: Dive into CRIS Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Analysts Have Been Trimming Their Curis, Inc. (NASDAQ:CRIS) Price Target After Its Latest Report
GuruFocus.com
7 days ago
Curis Inc (CRIS) Q3 2025 Earnings Call Highlights: Promising Study Results and Financial ...
Zacks
7 days ago
Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
Associated Press Finance
7 days ago
Curis: Q3 Earnings Snapshot
PR Newswire
7 days ago
Curis Provides Third Quarter 2025 Business Update
PR Newswire
14 days ago
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
GOBankingRates
5 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
5 months ago
3 International Vacations That Are Cheaper Than an iPhone
Compare CRIS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.